You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. NMDA Receptor Subtype Selective Modualtors as Alzheimer's Disease Therapeutics

    SBC: NEUROP, INC.            Topic: NIA

    DESCRIPTION (provided by applicant): Alzheimer's disease (AD) is a devastating neurodegenerative disorder. One of the few drugs used to treat AD is memantine, which inhibits N-methyl-d-aspartate receptors (NMDARs), glutamate receptor subtypes found at nearly all vertebrate excitatory synapses. NMDARs are critically involved in many aspects of nervous system function, including learning and me ...

    STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  2. New Class of Bright, Sharp, Tunable Near-Infrared Fluorophores for Flow Cyto

    SBC: Nirvana Sciences, Inc.            Topic: NIAID

    DESCRIPTION (provided by applicant): Polychromatic flow cytometry [FC] is one of the most powerful analytical techniques routinely used in immunology. Flow cytometry plays a critical role in several growing clinical applications: leukemia and lymphoma immunophenotyping for diagnosis and sub-categorization (now using 8-10 colors); in CD4/CD8 measurement in HIV-positive patients; and in HLA typing f ...

    STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  3. Enable Early and Sensitive In Vivo Detection of Liver Metastasis by Protein-based

    SBC: INLIGHTA BIOSCIENCES L.L.C.            Topic: NCI

    DESCRIPTION (provided by applicant): The major barriers limiting the application of MRI to detect small liver lesions and metastasis at the early stage and patient selection for targeted therapy based on molecular imaging of disease biomarkers, are due tothe lack of desired MRI contrast agents capable of enhancing the contrast between normal liver tissues and tumors with high relaxivity, tumor tar ...

    STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  4. Non-ATP competitive inhibitors of cyclin dependent kinases as cancer therapeutics

    SBC: PPI PHARMACEUTICALS, LLC            Topic: NCI

    DESCRIPTION (provided by applicant): As cancer is one of the leading causes of death in the United States with some sub-types remaining essentially untreatable, expansion of available drug targets will provide significant new options for the development ofmore effective antineoplastic agents. The major goal of this project is to apply a unique drug discovery strategy to cancer drug development. Th ...

    STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  5. AAV2-ASPA-Based Metabolic Intervention for Alzheimer's Disease

    SBC: ASKLEPIOS BIOPHARMACEUTICAL, INC.            Topic: NIA

    Abstract We propose to initiate preclinical development of a gene therapeutic targeted to Alzheimer's Disease. The World Health Organization's and Alzheimer's Disease International's report on Dementia (2012) recognizes that the global burden of AlzheimerDisease is forecast to worsen significantly with prevalence predicted to double every 20 years. Interventions that could prov ...

    STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  6. F10: a novel therapeutic to treat refractory or relapsed AML

    SBC: SOUTHEAST TECHINVENTURES INC            Topic: NCI

    DESCRIPTION (provided by applicant): Acute myeloid leukemia (AML) affected ~14,600 new patients in 2013 in the US and caused over 10,000 deaths, primarily in older adults. The current chemotherapy regimen, a combination of cytarabine (AraC) and anthracyclines such as daunorubicin (DNR), has resulted in 5-year survival rates of only 30-40% (less than 10% in patients over 60 years old). The principa ...

    STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  7. A Millimeter-wave Tunable Cavity for Ultra-sensitive Solids and Liquids DNP-NMR at Low Budget

    SBC: DOTY SCIENTIFIC, INC.            Topic: NIA

    ? DESCRIPTION (provided by applicant): NMR is probably the most powerful and widely used analytical technique for structure determination and function elucidation of molecules of all types, but it suffers from low sensitivity, particularly for insoluble biological macromolecules. Dynamic Nuclear Polarization (DNP) with Magic Angle Spinning (MAS) has recently demonstrated S/N gains exceeding t ...

    STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  8. Development of fluorescence-based receptor binding assays for the detection

    SBC: SEATOX RESEARCH INC            Topic: NIEHS

    DESCRIPTION (provided by applicant): Harmful algal blooms (HABs) are becoming frequent occurrences off the coasts of the United States, particularly in coastal waters of New England, the Gulf of Mexico, and the Pacific Ocean. Historically, HABs have beenassociated with fish kills and marine mammal mortalities; however, their effects on human health and economic loss due to HAB contamination of se ...

    STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  9. New generation of catheters for treatment of atrial fibrillation

    SBC: NOCTURNAL PRODUCT DEVELOPMENT, LLC            Topic: NHLBI

    DESCRIPTION (provided by applicant): Atrial fibrillation remains the most commonly occurring cardiac arrhythmia. It is associated with a lower quality of life and a higher rate of morbidity and mortality. Cryotherapy and radiofrequency catheter ablations for the purpose of eliminating atrial fibrillation have become a mainstream treatment option. They produce lesions that block the spread of elect ...

    STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  10. POC 2-D Diffusion Assay for self-monitoring of BNP

    SBC: SENTILUS            Topic: NHLBI

    DESCRIPTION (provided by applicant): The objective of this STTR proposal is to develop a 2-D diffusion point-of-care assay (POC) for B-type natriuretic peptide (BNP). The primary goal of the proposed work is to create a test format that will allow patientswith chronic heart failure to quantitatively self-monitor serum levels of BNP. Determination of baseline level of BNP and changes in this level ...

    STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government